Merck

September 14, 2018September 14, 2018

Keytruda and Chemotherapy Combo Now 1st-Line Treatment for Advanced NSCLC in EU

News

The European Commission approved the use of Keytruda (pembrolizumab), in combination with Alimta (pemetrexed) and platinum-based chemotherapy, as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). The approval is ... Read more

August 14, 2018August 14, 2018

FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo for Advanced Endometrial Carcinoma

News

The U.S. Food and Drug Administration granted breakthrough therapy designation to an investigational combination of Eisai’s Lenvima (lenvatinib) and Merck‘s Keytruda (pembrolizumab) for the treatment of patients with a subset of advanced endometrial carcinoma. Specifically, ... Read more

June 15, 2018June 15, 2018

Keytruda-Chemo Combo Shows Superior Anti-cancer Response in Metastatic NSCLC Phase 3 Trial

News

Adding Keytruda (pembrolizumab) to chemotherapy provides superior and more sustained tumor size reduction in patients with a type of metastatic non-small cell lung cancer (NSCLC), Merck’s Phase 3 trial ... Read more

June 6, 2018June 6, 2018

Foundation Medicine and Merck Collaborating to Develop Diagnostic Tests for Keytruda

News

Foundation Medicine will develop companion diagnostic tests for use with Keytruda (pembrolizumab) in collaboration with Merck (known as MSD outside the U.S. and Canada), Keytruda’s maker. “By collaborating, Merck and Foundation Medicine can ... Read more

May 29, 2018May 29, 2018

First Lung Cancer Patient Treated with NEO-PV-01 Vaccine in Phase 1 Trial

News

Neon Therapeutics has dosed the first lung cancer patient with its investigational vaccine NEO-PV-01, in combination with the checkpoint inhibitor Keytruda (pembrolizumab) and chemotherapy, in a Phase 1b clinical trial. ... Read more

May 2, 2018May 2, 2018

EMA to Review Keytruda Combo as First-line Treatment for Advanced NSCLC Patients in EU

News

The European Medicines Agency (EMA) has started the review process for Merck‘s application seeking approval of Keytruda (pembrolizumab) in combination with Alimta (pemetrexed) and platinum chemotherapy as a first-line treatment for ... Read more

April 20, 2018April 20, 2018

SD-101 and Keytruda Combo Fights Head and Neck Tumors, Trial Shows

News

A combination of Dynavax Technologies’ immunotherapy SD-101 and Keytruda triggered tumor-fighting responses in a third of patients with an advanced head and neck cancer, a Phase 1b/2 clinical trial showed. The response rate was double the 15 ... Read more

April 16, 2018April 16, 2018

First Stage of Bemcentinib-Keytruda Phase 2 Trial for Lung Cancer Completes Patient Enrollment

News

The first part of a Phase 2 trial investigating the AXL inhibitor bemcentinib in combination with Keytruda (pembrolizumab) in advanced non-small cell lung cancer (NSCLC) patients has completed enrollment of the planned ... Read more

April 13, 2018April 13, 2018

Keytruda Beats Chemo at Increasing NSCLC Patients’ Survival, Phase 3 Trial Shows

News

Non-small cell lung cancer (NSCLC) patients with PD-L1 protein in their tumors lived significantly longer when treated with the immunotherapy Keytruda (pembrolizumab) than standard platinum-based chemotherapy, a Phase 3 clinical ... Read more

April 11, 2018April 11, 2018

Keytruda-Epacadostat Combo Fails Primary Goal in Phase 3 Trial for Melanoma, Companies Announce

News

A Phase 3 clinical trial evaluating a combination of Keytruda and epacadostat in metastatic melanoma patients will be stopped after the combo failed the study’s first primary goal, Incyte Corporation and Merck announced. ... Read more

Pin It on Pinterest